Novartis Pharma AG: Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses
Pivotal results for efficacy and safety of Cosentyx (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology
United States Isabella Zinck Michael Meo Rachel Fink Thoma Hidradenitis Suppurativa Nicole Zinsli Somm
Source: finanznachrichten.de